Haleon plc (NYSE:HLN) Shares Bought by Focus Partners Wealth

Focus Partners Wealth increased its holdings in Haleon plc (NYSE:HLN - Free Report) by 132.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 67,928 shares of the company's stock after buying an additional 38,651 shares during the period. Focus Partners Wealth's holdings in Haleon were worth $686,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Sierra Ocean LLC acquired a new position in Haleon during the 4th quarter valued at about $26,000. Geneos Wealth Management Inc. acquired a new position in Haleon during the 4th quarter valued at about $35,000. FIL Ltd boosted its stake in Haleon by 45.7% during the 4th quarter. FIL Ltd now owns 4,049 shares of the company's stock valued at $39,000 after purchasing an additional 1,270 shares during the period. Spire Wealth Management acquired a new position in Haleon during the 4th quarter valued at about $39,000. Finally, Addison Advisors LLC boosted its stake in Haleon by 28.7% during the 4th quarter. Addison Advisors LLC now owns 4,954 shares of the company's stock valued at $47,000 after purchasing an additional 1,106 shares during the period. 6.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

HLN has been the subject of a number of analyst reports. Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Haleon in a research note on Monday, March 3rd. HSBC reissued a "hold" rating on shares of Haleon in a research note on Wednesday, March 5th. Barclays reissued an "overweight" rating on shares of Haleon in a research note on Tuesday, May 6th. Wall Street Zen lowered shares of Haleon from a "buy" rating to a "hold" rating in a research note on Thursday. Finally, Hsbc Global Res lowered shares of Haleon from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, March 5th. Six analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Haleon currently has an average rating of "Moderate Buy" and a consensus price target of $11.25.

Haleon Price Performance

HLN traded up $0.10 during trading on Friday, reaching $11.16. The stock had a trading volume of 20,774,144 shares, compared to its average volume of 8,245,055. The firm has a market capitalization of $50.30 billion, a price-to-earnings ratio of 32.82, a price-to-earnings-growth ratio of 2.82 and a beta of 0.24. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. Haleon plc has a 1-year low of $8.25 and a 1-year high of $11.19. The stock has a 50 day moving average of $10.30 and a two-hundred day moving average of $9.91.

Haleon (NYSE:HLN - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported $0.05 earnings per share for the quarter. The firm had revenue of $3.54 billion during the quarter, compared to the consensus estimate of $3.38 billion. Haleon had a return on equity of 14.76% and a net margin of 10.85%. As a group, equities analysts anticipate that Haleon plc will post 0.43 EPS for the current fiscal year.

Haleon Increases Dividend

The company also recently announced a -- dividend, which will be paid on Thursday, June 5th. Shareholders of record on Friday, April 25th will be given a $0.1166 dividend. This represents a yield of 1.6%. This is an increase from Haleon's previous -- dividend of $0.05. The ex-dividend date is Friday, April 25th. Haleon's dividend payout ratio is 58.97%.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.